Lexicon Pharmaceuticals, Inc. filings document a biopharmaceutical issuer with common stock listed on The Nasdaq Capital Market under LXRX. Its regulatory record includes Form 8-K reports on operating and financial results, clinical and regulatory updates, material agreements, debt financing, equity offerings and conversions of preferred stock into common stock.
Proxy and governance filings describe director elections, executive compensation, equity incentive plans and shareholder voting matters. Registration and prospectus-related disclosures address common-stock issuance programs, capital structure and public-market financing alongside the company's development programs in cardiometabolic and neurologic disease areas.
Artal Participations S.a r.l., a major holder in Lexicon Pharmaceuticals (LXRX), reported receiving an additional 41,289.58 shares of Lexicon’s Series B Convertible Preferred Stock at $65.00 per share on February 17, 2026. This purchase was made under a preferred stock purchase agreement tied to the underwriter’s partial exercise of its option to buy additional Lexicon common stock in an underwritten public offering.
Each share of this preferred stock will automatically convert into 50 shares of common stock once shareholders approve the conversion and other stated conditions are satisfied; until then, the shares are not convertible. After this transaction, Artal Participations S.a r.l. holds a total of 408,434.70 shares of Series B Convertible Preferred Stock indirectly, with related Artal entities and their principals disclaiming beneficial ownership except for any pecuniary interest described.
Lexicon Pharmaceuticals director Raymond Debbane reported open-market purchases of 268,497 shares of common stock over three days. He bought 57,952 shares on February 13 at a weighted average price of about $1.3093, 76,857 shares on February 17 at about $1.3082, and 133,688 shares on February 18 at about $1.32 per share, all in multiple transactions within narrow intraday price ranges. After these purchases, his directly held stake increased to 1,654,186 shares of Lexicon common stock. The filing also lists indirect ownership positions held through Avicenna Life Sci Master Fund LP and several Invus-affiliated entities, with millions of additional shares reported as indirectly owned.
Lexicon Pharmaceuticals insider compensation grant: SVP of Human Resources Wendy McDermott received equity awards on February 12, 2026. She acquired 250,200 restricted stock units, each representing a contingent right to one share of common stock, all held directly after the grant.
She was also granted stock options for 375,300 shares of common stock at an exercise price of $1.37 per share, also held directly. The restricted stock units vest in three equal installments each February 28 in the three years after the grant year, while the options vest 25% on the first anniversary of grant and then 1/48th per month with continued service.
Lexicon Pharmaceuticals reported that SVP, Partnerships & Corporate Strategy Rachel Yap Martens received new equity awards on February 12, 2026. She was granted 193,740 restricted stock units, each representing one future share of common stock, and a stock option for 290,620 shares at an exercise price of $1.37 per share.
The restricted stock units vest in three equal installments on February 28 of each of the three years after the grant year. The stock option vests 25% on the first anniversary of grant, then in equal monthly installments over the following three years, subject to continued service.
Lexicon Pharmaceuticals executive Craig B. Granowitz, SVP and Chief Medical Officer, reported new equity awards. On February 12, 2026, he received 346,610 restricted stock units, each representing one share of common stock, and a stock option for 519,920 shares with a $1.37 exercise price.
The restricted stock units vest in three equal installments on February 28 of each of the three years following the grant year. The option vests 25% on the first anniversary of grant, with the remaining 75% vesting in equal monthly installments over the next 36 months, conditioned on continued service.
Lexicon Pharmaceuticals granted equity awards to senior vice president of discovery Suma Gopinathan. On February 12, 2026, she acquired 238,450 restricted stock units, each representing one share of common stock, and a stock option for 357,680 shares at an exercise price of $1.37 per share.
The RSUs vest in three equal installments on February 28 of each of the three years following the grant year. The option vests 25% on the first anniversary of grant, then 1/48th of the shares each month of continued service until fully vested by February 12, 2036.
Lexicon Pharmaceuticals, Inc. reported equity awards to senior vice president Lisa DeFrancesco. On February 12, 2026, she received 257,530 restricted stock units, each representing a right to one share of common stock, and 386,300 stock options with a $1.37 exercise price.
The restricted stock units vest in three equal installments on February 28 of each of the three years after the grant year. The stock options vest 25% on the first anniversary of grant, with the remaining portion vesting monthly over the following three years, contingent on continued service.
Lexicon Pharmaceuticals executive Brian T. Crum, SVP, General Counsel and Secretary, reported equity awards on February 12, 2026. He was granted 299,710 restricted stock units, each representing the right to receive one share of common stock as they vest.
The restricted stock units vest in three equal installments on February 28 of each of the three years following the grant year. Crum was also granted a stock option for 449,560 shares at an exercise price of $1.37 per share, vesting 25% after one year and the remainder in equal monthly installments over the next three years.
Lexicon Pharmaceuticals SVP and CFO Scott M. Coiante received new equity awards as part of his compensation. On February 12, 2026, he was granted 272,680 restricted stock units, each representing a contingent right to one share of common stock. These RSUs vest in three equal installments on February 28 of each of the three years after the grant year.
On the same date, he also received 409,020 stock options with an exercise price of $1.37 per share, expiring on February 12, 2036. The option vests 25% on the first anniversary of grant, then in equal monthly installments over the following three years, all held as direct ownership.
Lexicon Pharmaceuticals’ Chief Executive Officer and director Michael Exton reported equity awards dated February 12, 2026. He received 862,440 restricted stock units, each representing a right to one share of common stock. These restricted stock units vest in three equal installments on February 28 of each of the three years following the grant year.
He was also granted a stock option for 1,293,670 shares of common stock at an exercise price of $1.37 per share. The option vests 25% on the first anniversary of the grant date and then 1/48th of the shares each month of continued service thereafter.